Production (Stage)
Coya Therapeutics, Inc.
COYA
$5.63
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 12,795.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12,795.00% | -- | |||
| Cost of Revenue | 169.13% | -12.88% | |||
| Gross Profit | -156.07% | 12.97% | |||
| SG&A Expenses | 26.94% | -3.67% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 94.38% | -8.27% | |||
| Operating Income | -88.15% | 8.31% | |||
| Income Before Tax | -100.95% | 9.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -150.59% | 27.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -150.59% | 27.49% | |||
| EBIT | -88.15% | 8.31% | |||
| EBITDA | -88.29% | 8.32% | |||
| EPS Basic | -145.09% | 32.51% | |||
| Normalized Basic EPS | -96.62% | 15.87% | |||
| EPS Diluted | -145.09% | 32.51% | |||
| Normalized Diluted EPS | -96.62% | 15.87% | |||
| Average Basic Shares Outstanding | 2.22% | 7.46% | |||
| Average Diluted Shares Outstanding | 2.22% | 7.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||